Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and a positive for Bristol Myers (BMY), whose schizophrenia drug Cobenfy was approved this past September and now is poised to have less commercial competition. Both AbbVie’s emraclidine and Bristol’s Cobenfy were acquired from acquisitions Cereval and Karuna, respectively, notes the analyst, who expects AbbVie shares to be weak after the company announced its two Phase 2 trials – EMPOWER-1 and -2 – evaluating emraclidine in schizophrenia did not meet their primary endpoint versus placebo. The firm has Buy ratings on both stocks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie falls -11.1%
- Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
- AbbVie’s emraclidine did not meet endpoint in Phase 2 schizophrenia trials
- AbbVie price target raised to $221 from $212 at Guggenheim
- AbbVie price target raised to $180 from $175 at Deutsche Bank
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
